CTSV and renal cell carcinoma: These results suggest that Pra-B can act as an antimetastatic agent through suppressing CTSC and CTSV expression as well as migration and invasion through downregulating the EGFR–MEK–ERK signaling cascade in RCC cells (Figure 6).